|
 |
oxycodone HClThis page contains recent news articles, when available, and an overview of oxycodone HCl but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: oxycodone HCl (when available) Oxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes. For the treatment of diarrhoea, pulmonary oedema; For the relief of moderate to moderately severe pain Mechanism Of Action: Oxycodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Oxycodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as Oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. News Articles on Oxycodone Sun Pharma gets USFDA approval for Oxycodone HCL - Apr 16, 2009 Sun Pharma has received a final approval to market Oxycodone Hydrochloride tablet in the strengths of 5 mg, 15 mg and 30 mg from the United States Food and Myiris.com Sun Pharmaceutical gets USFDA nod for Oxycodone HCL tablets - Apr 13, 2009 Drug firm Sun Pharmaceutical Industries has informed that the US health regulator Food & Drug Administration (FDA) has finally granted its subsidiary an Stock Watch Premier Research Announces Milestone New Drug Application - Mar 4, 2009 Acurox(R), a patented, orally administered, immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient, has a proposed PR Newswire (press release) 10-K: WATSON PHARMACEUTICALS INC - Feb 23, 2009 The decline in sales of oxycodone HCl controlled-release tablets was due to the termination of the distribution agreement in the first quarter of 2007. MarketWatch (press release) Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 ... - Feb 20, 2009 ...delayed-release capsules 40mg and increased sales of transdermal fentanyl was offset by a loss in revenue from oxycodone HCl extended-release tablets. Lifescience-online Covidien fiscal 1Q revenue rises 6.13% - Jan 26, 2009 ...boosted by higher sales of “dosage pharmaceuticals,â€? especially the new extended-release version of painkiller oxycodone HCl; Medical Supplies sales Providence Business News, King Pharmaceuticals Exercises Option to License Fourth Opioid ... - 25 Dec 2008 ...developing three other opioid analgesic product candidates utilizing Acura's Aversion(r) Technology, including Acurox(r) (oxycodone HCl/niacin) Tablets. MSNBC Watson Pharmaceuticals, Inc. - SWOT Analysis - companiesandmarkets ... - Dec 4, 2008 The increase was primarily driven by strong product sales of oxycodone HCl controlled-release tablets and pravastatin sodium tablets in its generics segment PR-Inside.com (Pressemitteilung), King Pharmaceuticals Reports Third-Quarter 2008 Financial Results - Nov 6, 2008 ACUROX ® Tablets, an investigational drug, is an orally administered immediate-release tablet containing oxycodone HCl as an active analgesic ingredient, istockAnalyst.com (press release), Acura Pharmaceuticals and King Pharmaceuticals Announce Positive ... - Oct 13, 2008 Study 111 results demonstrate that Acurox(tm) Tablets are disliked compared to oxycodone HCl tablets alone when excess doses are swallowed. GlobeNewsWire (press release), Acura Pharma, King Pharma say study assessing abuse liability ... - Oct 13, 2008 Acurox tablets contain a unique composition of oxycodone HCl, niacin, and essential functional inactive ingredients, and are intended to relieve moderate to RTT News, Drug for Pain ‘Significantly Disliked’ in Excess Doses, Company Says - Oct 14, 2008 Acurox tablets contain a composition of oxycodone HCl, niacin and essential functional inactive ingredients. The randomized, double-blind assessment of the FDA news (subscription), ACUR: Positive Top Line Results from Ph II Trial of Acurox(TM) - Oct 13, 2008 Study 111 results demonstrate that Acurox(tm) Tablets are disliked compared to oxycodone HCl tablets alone when excess doses are swallowed. Trading Markets (press release), Market Report -- In Play (ACUR) - Oct 13, 2008 Study 111 results demonstrate that Acurox(tm) Tablets are disliked compared to oxycodone HCl tablets alone when excess doses are swallowed. MSN Money Purdue Announces Resolution of OxyContin Patent Lawsuit - Sep 3, 2008 STAMFORD, CT - Purdue Pharma LP of Stamford, Connecticut and Mallinckrodt Inc. of Hazelwood, Missouri have agreed to end the OxyContin (oxycodone HCl ag-IP-news Agency, Oxycontin- Useful, But Deadly if Abused - Aug 26, 2008 Oxycodone HCl ER comes in small oval, light green tablets. One side of the tablet is labeled “93,â€? the other side is labeled “33.â€? 4. TransWorldNews (press release), King Pharmaceuticals Reports Second-Quarter 2008 Financial Results - 07 Aug 2008 ACUROXâ„¢ Tablets, an investigational drug, is an orally administered immediate-release tablet containing oxycodone HCl as an active analgesic ingredient, Business Wire (press release), King Pharmaceuticals Reports Second-Quarter 2008 Financial Results - 07 Aug 2008 ACUROX(TM) Tablets, an investigational drug, is an orally administered immediate-release tablet containing oxycodone HCl as an active analgesic ingredient, Trading Markets (press release), Acura Pharma gets $5 million fee from King Pharma - Jun 30, 2008 Acurox tablets contain the opioid oxycodone HCl, niacin and several functional inactive ingredients. The drug is designed to relieve pain while deterring Forbes, Treating Pain Effectively - New Study Results Confirm Improved ... - Jun 15, 2008 The 50 mg and 75 mg tapentadol IR treatment groups showed similar efficacy to that seen in patients treated with 10 mg of oxycodone HCl IR. Medical News Today (press release), Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study - Jun 17, 2008 Acurox(tm) Tablets contain a unique composition of the opioid oxycodone HCl, niacin, and several functional inactive ingredients and are intended to relieve Primenewswire (press release), Acura Pharmaceuticals, Inc. Receives $5.0 Million Milestone Payment - Jun 30, 2008 Compared to placebo, Acurox(tm) (oxycodone HCl and niacin) Tablets 5/30mg and 7.5/30mg both met the primary pain relief endpoint with p=.0001 and p less Trading Markets (press release), ACUR: receives $5M Milestone from King Pharmaceuticals for Acurox(TM) - Jun 30, 2008 Compared to placebo, Acurox(TM) (oxycodone HCl and niacin) Tablets 5/30mg and 7.5/30mg both met the primary pain relief endpoint with p=.0001 and p less Trading Markets (press release), Acura's Phase III pain drug study meets end point - Jun 18, 2008 One treatment arm received a dose of two Acurox (oxycodone HCl/niacin) tablets 5/30mg, a second treatment arm received a dose of two Acurox tablets 7.5/30mg Trading Markets (press release), King Pharmaceuticals Reports First-Quarter 2008 Financial Results - May 8, 2008 ACUROXâ„¢ Tablets, an investigational drug, is an orally administered immediate-release tablet containing oxycodone HCl as an active analgesic ingredient, Business Wire (press release), King Pharmaceuticals Exercises Option to License Third Opioid ... - May 27, 2008 The Agreement provides King with an exclusive license to ACUROX(tm) (oxycodone HCl, niacin, and functional inactive ingredients) tablets and another Primenewswire (press release), Tapentadol Effective for Chronic Pain Due to Knee Osteoarthritis ... - Apr 16, 2008 ..."Also, tapentadol ER 100 mg was associated with an efficacy outcome similar to oxycodone HCl CR 20 mg." Osteoarthritis is the most common form of arthritis. DG News Watson Pharma swings to profit - Feb 20, 2008 Generic product sales for the fourth quarter fell to $343.7 million from $412.8 million, primarily for the loss of revenue from oxycodone HCl Forbes, Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... - Feb 20, 2008 Generic product sales for the fourth quarter of 2007 decreased $69.0 million to $343.7 million, primarily related to the loss of revenue from oxycodone HCl PharmaLive.com (press release), King Pharmaceuticals Reports Year-End and Fourth-Quarter 2007 ... - Feb 28, 2008 These include REMOXY(TM) (long-acting oral oxycodone) and ACUROX(TM) Tablets (oxycodone HCl, niacin, and a unique combination of other ingredients), Centre Daily Times, OTCPicks.com Daily Market Movers Digest Midday Report - Feb 1, 2008 ...the Aversion Technology with oxycodone HCl as the active analgesic ingredient in an immediate release tablet intended for oral administration. TransWorldNews (press release), King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to ... - Oct 31, 2007 ACUROX(TM) (formerly oxyadf) is an orally administered immediate release tablet containing oxycodone hcl as an active analgesic ingredient, CNNMoney.com King signs agreement with Acura to develop pain drugs - Nov 2, 2007 By Staff Writer The companies have initially targeted four immediate release opioid analgesic products, including Acurox tablets (oxycodone hcl, niacin, Pharmaceutical Business Review Watson Pharmaceuticals Reports Third Quarter 2007 Results - Nov 6, 2007 Generic product sales for the third quarter of 2007 decreased $21.4 million to $326.2 million, primarily related to the loss of revenue from oxycodone hcl CNNMoney.com Centrally Acting Analgesic Tapentadol - Latest Phase II Data for ... - Oct 1, 2007 Patients received an oral dose of either tapentadol IR 50 mg, tapentadol IR 100 mg, oxycodone HCl IR 10 mg, or placebo every 4 to 6 hours over three days. Earthtimes.org Acura Secures Funding for OxyADF Trial - Aug 21, 2007 ...double-blind, placebo-controlled, multicenter, repeat-dose study of the safety and efficacy of OxyADF Tablets (oxycodone HCl and niacin). FDA news (subscription), Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal ... - Aug 20, 2007 ...the pivotal phase 3 trial for OxyADF (oxycodone HCl and niacin) Tablets, its lead product candidate utilizing Aversion(R) Technology. CNNMoney.com [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] Brand Names/Synonyms: oxycodone HCl is also known by the following brand names and/or synonymsCodeinone, Dihydrohydroxy-; Combunox; Dea No. 9143; Dihydrohydroxycodeinone; Dihydrohydroxycondeinone; Dihydrone; Dihydroxycodeinone; Dinarkon; Diphydrone; ENDOCET; ENDODAN; Endone; Eubine; Eubine [France]; Eucodal; Eucodalum; Eukodal; Eutagen; HSDB 3142; Ossicodone [Dcit]; Oxanest; Oxicodona [Inn-Spanish]; Oxicon; Oxicone; Oxikon; Oxycet; Oxycodeinone; Oxycodon; Oxycodone; Oxycodone Hcl; Oxycodone Hydrochloride; Oxycodone [Usan:Ban:Inn]; Oxycodonum [Inn-Latin]; Oxycon; Oxycontin; PERCOCET; Pancodine; Percobarb; Percocet; Percodan; Roxicet; Roxicodone; Roxilox; Supendol [Canada]; Tecodin; Tekodin; Thecodine; Thekodin; Tylox Drug Category: oxycodone HCl is categorized under the following by the FDA: Narcotics; Antitussives; Analgesics, Opioid; Opiate Agonists; ATC:N02AA05 Dosage Forms: Tablet; Suppository Absorption: well absorbed from OxyContin® tablets with an oral bioavailability of 60% to 87% Interactions: Interactions for Oxycodone: The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants.. Chemical IUPAC Name: 4, 5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |